Scale-Up and Post-Approval Changes for OSD — SUPAC-IR-MR Guidelines Applied to Real Manufacturing Changes

The SUPAC classification matrix is 30 years old. It is also the framework FDA will use to evaluate your CBE-30 filing for the 5× batch size scale-up you are planning next quarter.

SUPAC combination change classification is the most common SUPAC error FDA encounters in CBE-30 filings.

SUPAC-IR Classification Matrix — Level 1/2/3 Boundaries for Batch Size, Equipment, and Site Changes, and the Combination Change Rule That Most Change Control Systems Miss

SUPAC-IR’s three-level classification exists specifically to calibrate regulatory scrutiny to actual quality risk, and the boundary that trips up more change control systems than any other is the reference point for batch size classification: SUPAC measures scale-up relative to the biobatch, the batch that generated the pivotal bioequivalence data, not relative to whatever batch size happens to be currently approved for commercial manufacturing. A scale-up staying within ten times the biobatch size qualifies for Annual Report treatment, while crossing that tenfold threshold escalates the change to Level 2, requiring multi-point dissolution comparison and CBE-30 filing — and a commercial batch that was itself already a meaningful multiple of the biobatch at approval can mean a seemingly modest further increase actually crosses the tenfold line relative to that original biobatch reference, even though it looks like a smaller jump relative to current commercial scale. Equipment changes follow a parallel logic, with same-type, same-operating-principle replacements generally qualifying for lighter treatment while changes in operating principle or design escalate further, and site changes scale similarly from same-campus moves through different-state relocations to genuinely different regulatory jurisdictions. The rule that consistently gets missed, though, is what happens when several of these changes occur simultaneously: a batch size increase, an equipment upgrade needed to accommodate that larger batch, and a minor excipient adjustment made during process optimization at the new scale are not evaluated as three independent low-risk changes each qualifying for Annual Report treatment — SUPAC requires the combination to be classified at whichever individual element carries the highest classification level, meaning a Level 2 equipment change embedded within an otherwise Level 1 combination pulls the entire filing up to Level 2 regardless of how minor the other elements were.

SUPAC-MR Level 3 Trigger and In Vivo BE Study Requirement — The ±10% Polymer Concentration Threshold That Escalates Scale-Up Plus Formulation Changes Beyond CBE-30

Modified release products face a meaningfully stricter classification standard than immediate release tablets under SUPAC-MR, precisely because the relationship between formulation composition and in vivo drug release is tighter and more consequential for an extended release matrix than for an immediate release tablet. The specific trigger that escalates a change to Level 3, requiring a Prior Approval Supplement and an actual in vivo bioequivalence study, is any change to the rate-controlling polymer’s concentration exceeding roughly 10% of its approved level — a change from an approved level of 25% w/w HPMC to 28% w/w represents just over a 10% relative increase, and that alone is enough to trigger Level 3 classification regardless of how the rest of the manufacturing change package looks. This has a specific and easily underestimated consequence for combination changes: a batch size scale-up that would independently qualify as only a Level 2 change, requiring nothing more than a dissolution comparison and CBE-30 filing, gets pulled up to Level 3 the moment it’s combined with a polymer concentration adjustment crossing that 10% threshold, and unlike SUPAC-IR’s Level 3 pathway for immediate release products, which retains certain dissolution-based exceptions in specific circumstances, SUPAC-MR’s Level 3 requirement for an in vivo BE study generally cannot be satisfied by dissolution data alone. A CMC team experienced with SUPAC-IR classification, applying that same intuition to an ER product scale-up accompanied by what seems like a routine formulation adjustment, is exactly the profile most likely to under-classify a change that actually requires a full bioequivalence study before it can proceed.

Multi-Point Dissolution Comparison for Level 2 — Three-Medium f2 ≥50 Execution, PPQ at New Scale, and the CBE-30 vs. PAS Filing Timeline Implications

A Level 2 SUPAC-IR change earns its CBE-30 filing eligibility through dissolution comparison data generated across all three required media, not a single favorable medium, comparing a full set of dosage units from the changed process against the same number from the pre-change approved process and calculating the f2 similarity factor from the mean profiles in each medium independently. All three media need to clear the f2 ≥50 similarity threshold for the Level 2 classification to actually support a CBE-30 filing — a result below that threshold in even one of the three media means the change cannot proceed as filed, and the sponsor faces either further process optimization to bring dissolution back into alignment or an elevation to Level 3 treatment with the accompanying PAS and potential bioequivalence study that entails. Equipment changes carry an additional evidentiary burden beyond dissolution comparison alone: when a Level 2 equipment change is involved, process performance qualification batches manufactured at the new equipment scale need to be completed before the CBE-30 is filed, confirming the new equipment actually produces material meeting every NDA specification rather than assuming equivalence based on equipment type alone. The practical stakes of getting this classification and evidentiary package right extend directly to commercial supply continuity: a CBE-30 filing that actually should have been classified as Level 3, discovered only after commercial manufacturing has already begun at the new scale under the lighter filing, can force a product quarantine while the correct PAS pathway is pursued retroactively — a substantially worse outcome than simply classifying the change correctly from the outset.

The XGene SUPAC OSD Change Classification and Filing Architecture — Combination Classification, Biobatch Reference, Dissolution Protocol, SUPAC-MR Level 3 Triggers, and the Complete Post-Approval CMC Strategy

The XGene SUPAC OSD Change Classification and Filing Architecture is a structured post-approval manufacturing change classification and regulatory filing strategy built around the recognition that combination changes, not individual change elements, are where SUPAC classification most often goes wrong.

1. Combination Change Classification Protocol — Identify every simultaneous change element, classify each individually against the SUPAC-IR or SUPAC-MR matrix, and assign the combination to the highest individual classification level. 2. Biobatch Reference Point Determination — Anchor batch size classification to the original biobatch scale at approval, not the current commercial batch size. 3. SUPAC-IR Level 2 Dissolution Comparison Package — Execute the full three-medium f2 ≥50 protocol with PPQ batch data at the new equipment scale before filing. 4. SUPAC-MR Level 3 Trigger Identification — Screen every rate-controlling polymer concentration change against the ±10% threshold independent of any accompanying batch size change classification. 5. CBE-30 vs. PAS Filing Timeline Planning — Confirm the correct supplement pathway before implementation to avoid a retroactive quarantine from an under-classified filing.

The output is the SUPAC change management strategy that classifies combination changes correctly the first time, rather than discovering a Level 3 requirement after commercial manufacturing has already begun under an insufficient CBE-30.

FDA’s Guidance for Industry: SUPAC-IR Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes (1995) establishes the three-level classification matrix and combination change rule this article’s analysis is built around, while FDA’s Guidance for Industry: SUPAC-MR Extended Release Solid Oral Dosage Forms (1997) establishes the stricter Level 3 polymer concentration trigger applied to modified release products. 21 CFR 314.70 establishes the Annual Report, CBE-30, and PAS supplement categories, and FDA’s Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms (1997) establishes the f2 ≥50 multi-medium comparison standard.

For your most recent OSD post-approval manufacturing change, can you confirm today that the SUPAC classification was evaluated for the combination of all simultaneous changes, that the batch size classification used the biobatch scale as the reference point, and that any rate-controlling polymer concentration change was assessed against the ±10% Level 3 trigger threshold?